PressFebruary 14, 2023 PharmAla Biotech Closes Purchase Order With Emyria Ltd., Completes Filing of “LaNeo” Trademark in Australia
PressFebruary 14, 2023 Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results
PressFebruary 10, 2023 Mydecine Innovations Group Announces Closing Under Share Subscription Agreement
PressFebruary 10, 2023 Silo Pharma Inc. Partnering to Transform Health Care, Improve Patient Outcomes
PressFebruary 10, 2023 FSD Pharma Inc. Receipt of No Objection Letter from Health Canada Is Focus of Recent InvestmentPitch Media Video
PressFebruary 10, 2023 Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements
PressFebruary 10, 2023 Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
PressFebruary 8, 2023 Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists
PressFebruary 8, 2023 PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System
PressFebruary 8, 2023 Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
PressFebruary 6, 2023 Lobe Sciences Congratulates Australia for Becoming the First Nation to Approve the Medicinal Use of Psilocybin and MDMA
PressFebruary 6, 2023 Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL
PressFebruary 6, 2023 Seelos Therapeutics Doses First Patients in an Ethnobridging Study with SLS-002 (Intranasal Racemic Ketamine)
PressFebruary 3, 2023 Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch
PressFebruary 3, 2023 Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training using Psilocybe Cubensis Tea
PressFebruary 3, 2023 Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET
PressFebruary 3, 2023 PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease
PressFebruary 3, 2023 Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
PressFebruary 3, 2023 PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
PressFebruary 3, 2023 Psyence and Eden Labs Announce Extraction and Product Development Collaboration
